TITLE

Lopinavir

AUTHOR(S)
Hurst, M.; Faulds, D.
PUB. DATE
December 2000
SOURCE
Drugs;Dec2000, Vol. 60 Issue 6, p1371
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ Lopinavir is a protease inhibitor with high specificity for HIV-1 protease. Ritonavir strongly inhibits lopinavir metabolism; coadministration of lopinavir and ritonavir in healthy volunteers increased the area under the lopinavir plasma concentration-time curve >100-fold. ▴ Trough plasma concentration : antiviral 50% effective concentration ratio for lopinavir was >75 for wild-type HIV at the dose used in clinical trials, compared to values of ≤4 for other commonly used protease inhibitors. ▴ Coformulated lopinavir and ritonavir (lopinavir/ ritonavir) 400/100mg twice daily for 48 weeks suppressed HIV replication in significantly more antiretroviral-naive patients than nelfinavir 750mg 3 times daily (all patients also received stavudine and lamivudine). ▴ Suppression of viral replication was observed in most protease inhibitor-experienced patients with lopinavir/ ritonavir (400/100, 400/200 or 533/133mg twice daily for 48 or 96 weeks) in combination with ≥2 nucleoside reverse transcriptase inhibitors (NRTIs) and either efavirenz or nevirapine. ▴ 48 weeks of treatment with twice daily lopinavir/ ritonavir (230/57.5 or 300/75 mg/m for the first 12 weeks and then 300/75 mg/m) in combination with 1 or 2 NRTIs, with or without nevirapine, suppressed viral replication in the majority of antiretroviral-naive and -experienced paediatric patients (aged 6 months to 12 years). ▴ Diarrhoea, nausea and asthenia were the most frequently reported adverse effects in patients receiving lopinavir/ritonavir-based regimens. Elevated total cholesterol, triglyceride and hepatic enzyme levels were also reported.
ACCESSION #
9592876

 

Related Articles

  • PIs have new drug-drug interaction language.  // AIDS Alert;Jun2010, Vol. 25 Issue 6, p71 

    The article reports that the approved protease inhibitors by the U.S. Food and Drug Administration (FDA) for treatment of HIV-1 infection have new drug-drug interaction language.

  • Bortezomib enhanced chemotherapy in activated B cell-like relapsed DLBCL. Adams, Stacey L.; Haigh, Christen; Harris, Jason; Lawrence, Leah // Hem/Onc Today;7/25/2009, Vol. 10 Issue 14, p18 

    The article discusses a study on the role of bortezomib, a protease inhibitor, in increasing the activity of chemotherapy in activated B cell-like diffuse large B-cell lymphoma.

  • Saquinavir soft gelatin capsule: a comparative safety review. Gill, J.; Feinberg, J. // Drug Safety;Feb2001, Vol. 24 Issue 3, p223 

    The HIV-1 protease inhibitor (PI) saquinavir is available as a soft gelatin capsule (SGC) formulation. At the recommended dosage of saquinavir SGC (1200mg 3 times daily), this formulation provides around 8-fold greater exposure than the established hard gelatin capsule (HGC) formulation at the...

  • Saquinavir Soft-Gel Capsule: An Updated Review of its Use in the Management of HIV Infection. Figgitt, D.P.; Plosker, G.L. // Drugs;Aug2000, Vol. 60 Issue 2, p481 

    Saquinavir is a potent and highly selective HIV protease inhibitor. Initially formulated as a hard-gel capsule (HGC), saquinavir was the first protease inhibitor available commercially for the treatment of patients with HIV infection. The limited oral bioavailability of saquinavir HGC has been...

  • American Diabetes Association.  // BioWorld Today;6/29/2010, Vol. 21 Issue 124, p6 

    The article reports on data presented by Bristol-Myers and AstraZeneca plc, which showed that dipeptidyl peptidase-4 (DPP-4) inhibitor Onglyza or saxagliptin plus metformin was noninferior to the sulfonylurea glipzide plus metformin in patients who have inadequate glucose control on metformin alone.

  • Good News for Alzheimer's Drugs.  // BioWorld Today;6/28/2010, Vol. 21 Issue 123, Special section p1 

    This article focuses on a study by scientists at Washington University School of Medicine and Merck & Co. Inc. which examined the effects of a class of drugs called gamma secretase inhibitors.

  • Bortezomib.  // Reactions Weekly;10/9/2010, Issue 1322, p9 

    The article describes the case of a 59-year-old man who developed peripheral neuropathy during treatment with proteosome inhibitor bortezomib for treatment-resistant multiple myeloma.

  • Bortezomib.  // Reactions Weekly;10/9/2010, Issue 1322, p9 

    The article describes the case of a woman in her forties taking bortezomib for antibody-mediated rejection of kidney transplant who developed thrombocytopenia after the second dose of proteosome inhibitor bortezomib.

  • Metabolic side effects observed with protease inhibitors.  // AIDS Patient Care & STDs;May98, Vol. 12 Issue 5, p405 

    Reports on the metabolic side effects associated with the use of protease inhibitors, which were presented at the 5th Conference on Retroviruses and Opportunistic Infections. Identification of one of the side effects; Indication that switching to another inhibitor will not change the condition;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics